Semaglutide caused gastroparesis requiring hospitalization after skipping dose titration steps
A 48-year-old diabetic woman developed gastroparesis with acute kidney injury and colitis after resuming semaglutide at 2 mg weekly without the recommended stepwise dose escalation.
Quick Facts
What This Study Found
Gastroparesis after semaglutide 2 mg resumed without titration. Complications: AKI from dehydration + left-sided colitis. Treatment: metoclopramide + semaglutide cessation → resolution.
Key Numbers
How They Did This
Single case report.
Why This Research Matters
Many patients restart GLP-1 drugs at prior doses after breaks, not realizing the body loses tolerance. This case demonstrates that dose re-titration is essential to prevent serious GI complications.
The Bigger Picture
As GLP-1 drug shortages lead to on-off-on usage patterns, cases like this will become more common. Re-education about dose titration after treatment breaks is critical.
What This Study Doesn't Tell Us
Single case. Gastroparesis may have pre-existed. Other contributing factors possible. Cannot establish incidence.
Questions This Raises
- ?Should all GLP-1 restarters undergo full dose re-titration?
- ?Does diabetic gastroparesis predispose to semaglutide-induced GI complications?
- ?How common is gastroparesis with rapid GLP-1 dose escalation?
Trust & Context
- Key Stat:
- Skipped titration = gastroparesis Restarting semaglutide at full dose (2 mg) without titration caused stomach paralysis, kidney injury, and colitis requiring hospitalization
- Evidence Grade:
- Single case report.
- Study Age:
- Published in 2025.
- Original Title:
- Unmasking Semaglutide-Induced Gastroparesis: The Dangers of Rapid Dose Escalation in a Diabetic Patient.
- Published In:
- Cureus, 17(9), e91679 (2025)
- Authors:
- Singhal, Rohan, Sachdeva, Dheerja, Wortman Ii, Kevin, Lall, Rekha
- Database ID:
- RPEP-13621
Evidence Hierarchy
Frequently Asked Questions
What happens if you restart semaglutide at the full dose?
This case shows it can cause gastroparesis (stomach paralysis), which led to severe nausea, vomiting, dehydration, kidney damage, and colon inflammation. The recommended approach is to always restart from the lowest dose (0.25 mg) and gradually increase, even if you were previously on a higher dose.
What is gastroparesis?
Gastroparesis is a condition where the stomach cannot empty food normally, causing nausea, vomiting, and discomfort. GLP-1 drugs intentionally slow stomach emptying (which helps with appetite control), but too much too quickly—especially without dose titration—can effectively paralyze the stomach.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13621APA
Singhal, Rohan; Sachdeva, Dheerja; Wortman Ii, Kevin; Lall, Rekha. (2025). Unmasking Semaglutide-Induced Gastroparesis: The Dangers of Rapid Dose Escalation in a Diabetic Patient.. Cureus, 17(9), e91679. https://doi.org/10.7759/cureus.91679
MLA
Singhal, Rohan, et al. "Unmasking Semaglutide-Induced Gastroparesis: The Dangers of Rapid Dose Escalation in a Diabetic Patient.." Cureus, 2025. https://doi.org/10.7759/cureus.91679
RethinkPeptides
RethinkPeptides Research Database. "Unmasking Semaglutide-Induced Gastroparesis: The Dangers of ..." RPEP-13621. Retrieved from https://rethinkpeptides.com/research/singhal-2025-unmasking-semaglutideinduced-gastroparesis-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.